Daclatasvir for the treatment of chronic hepatitis C virus infection

Z. Temesgen; S. A. Rizza

doi:10.1358/dot.2015.51.5.2312449

Daclatasvir for the treatment of chronic hepatitis C virus infection

Z. Temesgen, S. A. Rizza

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

Original language	English (US)
Pages (from-to)	277-288
Number of pages	12
Journal	Drugs of Today
Volume	51
Issue number	5
DOIs	https://doi.org/10.1358/dot.2015.51.5.2312449
State	Published - May 1 2015

Keywords

BMS-790052
Daclatasvir
HCV NS5A inhibitors
Hepatitis C

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dot.2015.51.5.2312449

Cite this

@article{ea8d38cd72f14bfe8ac727012e420edf,

title = "Daclatasvir for the treatment of chronic hepatitis C virus infection",

abstract = "Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.",

keywords = "BMS-790052, Daclatasvir, HCV NS5A inhibitors, Hepatitis C",

author = "Z. Temesgen and Rizza, {S. A.}",

year = "2015",

month = may,

day = "1",

doi = "10.1358/dot.2015.51.5.2312449",

language = "English (US)",

volume = "51",

pages = "277--288",

journal = "Drugs of Today",

issn = "1699-3993",

publisher = "Prous Science",

number = "5",

}

TY - JOUR

T1 - Daclatasvir for the treatment of chronic hepatitis C virus infection

AU - Temesgen, Z.

AU - Rizza, S. A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

AB - Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.

KW - BMS-790052

KW - Daclatasvir

KW - HCV NS5A inhibitors

KW - Hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=84938596314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938596314&partnerID=8YFLogxK

U2 - 10.1358/dot.2015.51.5.2312449

DO - 10.1358/dot.2015.51.5.2312449

M3 - Article

C2 - 26097901

AN - SCOPUS:84938596314

SN - 1699-3993

VL - 51

SP - 277

EP - 288

JO - Drugs of Today

JF - Drugs of Today

IS - 5

ER -

Daclatasvir for the treatment of chronic hepatitis C virus infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this